Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 577

1.

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.

Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE.

Expert Opin Pharmacother. 2007 Jun;8(8):1039-58. Review.

PMID:
17516870
2.

Anthracycline cardiotoxicity in long-term survivors of childhood cancer.

Scully RE, Lipshultz SE.

Cardiovasc Toxicol. 2007;7(2):122-8. Review.

PMID:
17652816
3.

Anthracycline cardiotoxicity.

Jones RL, Swanton C, Ewer MS.

Expert Opin Drug Saf. 2006 Nov;5(6):791-809. Review.

PMID:
17044806
4.

Exposure to anthracyclines during childhood causes cardiac injury.

Lipshultz SE.

Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. Review.

PMID:
16781284
5.

[Cardiotoxicity of conservative treatment of solid tumors].

Sivak LA, Askol'skiĭ AV, Lial'kin SA, Klimanov MIu, Maĭdanevich NN, Kasap NV.

Lik Sprava. 2011 Apr-Jun;(3-4):51-9. Review. Russian.

PMID:
22416364
6.

Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.

Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A.

Health Technol Assess. 2007 Jul;11(27):iii, ix-x, 1-84. Review.

7.

Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.

Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, Calabrò R.

Paediatr Drugs. 2005;7(2):67-76. Review.

PMID:
15871628
8.

Pathogenesis of cardiotoxicity induced by anthracyclines.

Elliott P.

Semin Oncol. 2006 Jun;33(3 Suppl 8):S2-7. Review.

PMID:
16781283
9.

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.

Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, Palmieri C, Plummer CJ, Stanley A, Verrill MW.

Ann Oncol. 2009 May;20(5):816-27. doi: 10.1093/annonc/mdn728. Epub 2009 Jan 19. Review.

10.

Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.

Anderson B.

Pediatr Blood Cancer. 2005 Jun 15;44(7):584-8. Review.

PMID:
15700251
11.

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.

Swain SM, Vici P.

J Cancer Res Clin Oncol. 2004 Jan;130(1):1-7. Epub 2003 Oct 17. Review.

PMID:
14564513
12.

Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.

Jensen BV.

Semin Oncol. 2006 Jun;33(3 Suppl 8):S15-21. Review.

PMID:
16781285
13.

Monitoring of anthracycline-induced cardiotoxicity.

Jannazzo A, Hoffman J, Lutz M.

Ann Pharmacother. 2008 Jan;42(1):99-104. Epub 2007 Dec 19. Review.

PMID:
18094345
14.
15.

[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].

Goey AK, Schellens JH, Beijnen JH, Huitema AD.

Ned Tijdschr Geneeskd. 2010;154:A1155. Review. Dutch.

PMID:
20619024
16.

Prevention of anthracycline-induced cardiotoxicity in children: the evidence.

van Dalen EC, Caron HN, Kremer LC.

Eur J Cancer. 2007 May;43(7):1134-40. Epub 2007 Mar 26. Review.

PMID:
17383867
17.

Cardiotoxicity and cardioprotection during chemotherapy.

Hochster H, Wasserheit C, Speyer J.

Curr Opin Oncol. 1995 Jul;7(4):304-9. Review.

PMID:
7578376
18.
19.
20.

Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.

Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE.

Future Cardiol. 2012 Jul;8(4):647-70. doi: 10.2217/fca.12.44. Review.

Items per page

Supplemental Content

Write to the Help Desk